The latest update is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).
On March 18, 2025, Virax Biolabs Group Limited announced the commencement of patient enrollment for its UK-based, multi-center clinical study. This study, conducted in collaboration with the UK’s National Health Service, aims to assess the ViraxImmune™ FluoroSpot T cell assay’s performance in detecting T cell dysfunction in patients with post-acute infection syndromes, including long COVID, PTLD, and ME/CFS. The study plans to enroll up to 200 participants, with initial data expected in Q2 2026. This initiative could significantly impact the diagnostics and treatment of these conditions, potentially leading to earlier interventions and improved patient outcomes.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases. The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, particularly effective in diagnosing and treating post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
YTD Price Performance: -42.08%
Average Trading Volume: 346,831
Technical Sentiment Consensus Rating: Buy
For an in-depth examination of VRAX stock, go to TipRanks’ Stock Analysis page.